NCT01342939

Pathophysiological Implications of the Incretin Hormones in Maturity Onset of Diabetes of the Young (MODY)

Postprandial Secretion of of Incretin Hormones and Incretin Effect in Patients With Maturity-onset Diabetes of the Young (MODY)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 31 (actual)
• Sponsor: University Hospital, Gentofte, Copenhagen · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to describe the incretin effect and postprandial incretin response in patients with MODY2 and MODY3 and a group of matched healthy subjects. In sulphonyl urea treated subjects the purpose is also to compare the incretin effect with and without treatment. In healthy subjects the purpose is also to investigate the incretin effect under increased levels of endogen incretin hormones.

Detailed description

Comparison of of insulin secretion (AUC) during the experimental days. Furthermore a comparison of GIP, GLP1 and glucagon responses as well as plasma glucose levels.

Conditions

• Maturity-onset Diabetes of the Young

Interventions

Type	Name	Description
OTHER	Oral Glucose Tolerance Test (OGTT)	50g waterfree glucose dissolved in 300ml water consumed over 5 min.
OTHER	iso glycaemic intravenous (iv) glucose infusion (IIGI)	20% glucose
DIETARY_SUPPLEMENT	Meal test	Energy drink, 350ml (525 kcal: 65 g carbohydrates, 20 g fat and 21 g protein)
OTHER	Sitagliptin	Healthy control subject are given an acute dosage of 100mg the evening before the experimental day, and the same morning in order to increase levels of endogen incretin hormones
OTHER	Incretin effect on sulphonyl urea treatment	Subject with MODY who are treated with sulphonyl urea are investigated without medication break prior to examination.

Timeline

• Start date: 2011-01-01
• Primary completion: 2011-11-01
• Completion: 2011-12-01
• First posted: 2011-04-27
• Last updated: 2013-01-15

Locations

1 site across 1 country: Denmark